Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.76 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.76 |
| ▸ | CTSL | P07711 | 16/20 | 0.56 |
| ▸ | CTSS | P25774 | 14/20 | 0.55 |
| ▸ | CTSK | P43235 | 13/20 | 0.55 |
| ▸ | CTSB | P07858 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624191 | 0.87 | CTSL (0.71) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL13624187 | 0.87 | CTSL (0.70) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL14579994 | 0.87 | CTSL (0.70) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL2154979 | 0.87 | CTSL (0.70) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL24283661 | 0.86 | GRN (1.00) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL1169219 | 0.86 | CTSL (0.72) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL4085479 | 0.86 | CTSL (0.72) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL4085485 | 0.86 | CTSL (0.72) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL1169217 | 0.86 | CTSL (0.72) | GRNSORT1CTSLCTSSCTSK | |
| SCHEMBL4786346 | 0.86 | CTSL (0.72) | GRNSORT1CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | GRN 1362/4885SORT1 1642/4885CTSL 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.